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T cell-dependence of Lassa fever pathogenesis
Abstract
Lassa virus (LASV), the causative agent of Lassa fever (LF), is endemic in West Africa, accounting for
substantial morbidity and mortality. In spite of ongoing research efforts, LF pathogenesis and
mechanisms of LASV immune control remain poorly understood. While normal laboratory mice are
resistant to LASV, we report that mice expressing humanized instead of murine MHC class I (MHC-I)
failed to control LASV infection and develop severe LF. Infection of MHC-I knockout mice confirmed
a key role for MHC-I-restricted T cell responses in controlling LASV. Intriguingly we found that T cell
depletion in LASV-infected HHD mice prevented disease, irrespective of high-level viremia.
Widespread activation of monocyte/macrophage lineage cells, manifest through inducible NO synthase
expression, and elevated IL-12p40 serum levels indicated a systemic inflammatory condition. The
absence of extensive monocyte/macrophage activation in T cell-depleted mice suggested that T cell
responses contribute to deleterious innate inflammatory reactions and LF pathogenesis. Our
observations in mice indicate a dual role for T cells, not only protecting from LASV, but also enhancing
LF pathogenesis. The possibility of T cell-driven enhancement and immunopathogenesis should be
given consideration in future LF vaccine development.
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Abstract
Lassa virus (LASV), the causative agent of Lassa fever (LF), is endemic in West Africa, accounting for substantial morbidity
and mortality. In spite of ongoing research efforts, LF pathogenesis and mechanisms of LASV immune control remain poorly
understood. While normal laboratory mice are resistant to LASV, we report that mice expressing humanized instead of
murine MHC class I (MHC-I) failed to control LASV infection and develop severe LF. Infection of MHC-I knockout mice
confirmed a key role for MHC-I-restricted T cell responses in controlling LASV. Intriguingly we found that T cell depletion in
LASV-infected HHD mice prevented disease, irrespective of high-level viremia. Widespread activation of monocyte/
macrophage lineage cells, manifest through inducible NO synthase expression, and elevated IL-12p40 serum levels
indicated a systemic inflammatory condition. The absence of extensive monocyte/macrophage activation in T cell-depleted
mice suggested that T cell responses contribute to deleterious innate inflammatory reactions and LF pathogenesis. Our
observations in mice indicate a dual role for T cells, not only protecting from LASV, but also enhancing LF pathogenesis. The
possibility of T cell-driven enhancement and immunopathogenesis should be given consideration in future LF vaccine
development.
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Introduction
Lassa virus (LASV) is the causative agent of Lassa fever (LF) [1].
It accounts for an estimated number of 3009000 infections and
several thousand deaths in endemic areas each year [2], while
imported cases have been reported from around the globe [3]. The
virus is listed category A by the Center for Disease Control and
Prevention [4]. So far, LASV vaccines have remained unavailable
for clinical use, and Ribavirin, the only available therapy, has
shown limited efficacy [5]. The development of effective
vaccination strategies would therefore benefit from further insight
into the mechanisms of successful LASV immune control, as well
as into the processes underlying LF development and pathogenesis.
It is generally agreed upon that the level of tissue damage
observed at autopsy cannot by itself account for the severe nature
of LF. Therefore, as with other viral hemorrhagic fevers [6,7], a
contribution of the host response to LF pathogenesis has long been
a matter of debate. For instance, the manifestation of Dengue
Hemorrhagic Fever (DHF) has long been accredited to pre-
existing immunity [8,9]. Apart from serotype cross-reactive
antibodies [8,9], memory T cells were recently identified as
important players in the disease process [10], and susceptibility as
well as resistance to DHF have been linked to particular MHC
alleles [11,12]. In addition, infected monocytes and macrophages
play an important role in DHF by secreting inflammatory
cytokines [13,14].
Such contributions of the immune response to disease severity
can represent a major hurdle in vaccine development [15]. For
instance, formalin-inactivated vaccines to respiratory syncytial
virus (RSV) and measles virus resulted in enhanced morbidity and
mortality in response to natural infection [16,17]. Animal models
for RSV have since provided evidence that T cell subsets play an
important role in disease enhancement [16,18]. Interestingly,
innate immune cells including eosinophils and polymorphonuclear
granulocytes dominate the histological picture upon T cell-driven
enhancement of RSV [18]. Similarly, inflammatory macrophage
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responses were found to be a common feature of viral hemorrhagic
fevers [6]. In accordance with the ‘‘cytokine storm’’ hypothesis,
macrophage-derived inflammatory cytokines [19,20,21,22,23] and
nitric oxide (NO) [24,25] are candidate mediators of capillary
leakage and shock [26], and elevated levels of such mediators
correlate with increased disease severity and worsened clinical
outcome.
Still, LASV lacks a clear pathognomonic signature, and clinical
manifestations of LF are largely unspecific, making it difficult to
diagnose the infection accurately via clinical criteria alone [27]. In
contrast to other hemorrhagic fevers, coagulation abnormalities
and bleeding are largely absent in LF [27,28], leading some to
argue on pathological grounds that Lassa fever ought not be
considered a hemorrhagic fever at all [6,29]. More characteristic
of severe LF cases are the vascular leakage with edema and
effusions in the pleural and pericardial cavities [30,31,32]. At
necropsy, liver and lung count among the organs most commonly
affected during LF [29,30,31,32,33].
One of the few well-documented characteristics of primary
LASV-directed immune response is that neutralizing antibody
responses develop only weeks or months after the virus has been
eliminated [28]. Also studies of vaccination-induced LASV
immunity point toward a cell-mediated mechanism at the frontline
of antiviral defense [34,35]. Still, this notion remains to be
addressed and verified directly, and the responsible T cell subtypes
to be characterized. Further, a potential disease-enhancing effect
of T cell responses in LF has not yet been given sufficient
consideration.
Although normal laboratory mouse strains develop acute
disease of the central nervous system when infected with LASV
intracerebrally [1,28,36], they remain resistant to the systemic
disease so characteristic of human LF, irrespective of the route
used to infect them. Research on LF has therefore been limited to
the use of guinea pigs and non-human primates [28], complicating
mechanistic studies on immunity and pathogenesis. Here we
report on a series of experiments triggered by accidental
observations of serious disease in LASV-infected humanized mice
(HHD mice [37], C57BL/6 background). HHD mice are
genetically engineered to express a human/mouse-chimeric
HLA-A2.1 molecule instead of the murine MHC class I gene
products and are widely used to identify human HLA-A2.1-
restricted peptide epitopes. Stimulated by these unexpected results,
we were able to identify T cell-dependence of LASV control, but
also of LF pathogenesis. These findings, combined with the
propensity of LASV to target monocyte/macrophage lineage cells
in vivo, followed by T cell-dependent activation of this cell
population, provide a novel concept for virus-host relationship
and pathogenesis of LASV. We anticipate that such understanding
may aid rational refinement of both vaccine-mediated prevention
and treatment of LASV infection.
Results
MHC class I-dependent control of LASV infection
We first compared viral replication in HHD mice and wild type
C57BL/6 controls. C57BL/6 mice cleared LASV within about
seven days after infection whereas HHD mice remained viremic
for substantially longer periods of time (Fig. 1A and data not
shown). A detailed analysis of the initial phase of infection
documented a virtually immediate uptake of the inoculum into
tissues (no virus in blood 2.5 hours after inoculation), followed by
identical levels of viremia in wild type and HHD mice up to
around day 4 (Fig. 1A). This demonstrates that viremia reflected
viral replication in tissues rather than residual inoculum, and that
the early phase of virus replication was identical in HHD and
C57BL/6 mice. Clear differences in virus control became evident
no earlier than seven days after infection (Fig. 1A). These
differences in kinetics were compatible with differential adaptive
immune control in HHD and C57BL/6 mice. Given that MHC
class I (MHC-I) represents the only genetic difference between
HHD and C57BL/6 mice, these findings suggested that H-2Db/
H-2Kb-restricted T cell responses in C57BL/6 mice played an
important role in virus control. Hence, we extended our study to
further analyze the contribution of MHC-I- and MHC-II-
restricted T cell responses to LASV control (Fig. 1B). MHC-II-
deficient mice (lacking CD4+ T cells) efficiently resolved the
infection whereas MHC-I-deficient animals (MHC-I-/-; targeted
mutation of the b2-microglobulin gene; devoid of CD8+ T cells)
developed persistent high-level viremia. This corroborated the key
role of MHC-I-restricted T cell responses in LASV control and
indicated further that MHC-II-restricted responses were of lesser
importance. A time course analysis of viral titers in kidney, lung,
liver and spleen of LASV-infected HHD, C57BL/6 and MHC-I-/-
mice confirmed that viral replication was comparable on day 2
and day 4. By day 8, however, LASV in the organs of C57BL/6
mice approached the detection limit whereas comparably high
titers of virus persisted in tissues of HHD and MHC-I-/- mice.
These data provided additional independent support for the above
conclusions on productive replication of LASV in mice and the
key role of MHC-I-restricted T cells in its control.
T cell-dependent disease in LASV-infected HHD mice
Between 7 and 12 days after LASV infection, HHD mice
developed ruffled fur and reduced spontaneous activity. Some of
them rapidly and unexpectedly deteriorated and progressed to a
state of agony and death: Five out of twenty three mice (,22%)
infected in a total of five experiments succumbed to disease. In
contrast but in accordance with the literature, all thirteen wild type
C57BL/6 mice, serving as controls in three of these experiments,
survived without clinical evidence of disease. Elevated serum
aspartate aminotransferase activity (AST) represents the primary
Author Summary
Lassa virus (LASV) is the causative agent of Lassa fever (LF),
accounting for substantial morbidity and mortality in West
Africa. Yet the mechanisms leading to disease remain
poorly understood. Here we propose a concept whereby
the body’s immune defense either defeats LASV rapidly or,
if unsuccessful, becomes an essential facilitator of disease.
This latter paradoxical postulate stems from observations
in genetically engineered (HHD) mice, which we found to
be susceptible to LF. HHD mice differ from resistant wild
type mice in that they have a humanized repertoire of T
cells, a main component of the mammalian immune
system. Counterintuitively, we could protect HHD mice
against LF by experimentally removing their T cells. We
further found that LF correlated with widespread activa-
tion of macrophages, which again depended on T cells.
Similar to T cells, macrophages are important players in
our body’s defense system, but their inflammatory
products are also candidate mediators of LF. Taken
together, these findings suggest that LF may represent
an inappropriate host response to infection. Specifically,
our study demonstrates a two-faced role of T cell
responses against LASV. Such detrimental aspects of
immune defense need to be given consideration in future
LF vaccine development, to avoid enhancement of disease
in vaccinated individuals.
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parameter for monitoring LF, and AST combined with viremia
represent the best predictors for clinical outcome in humans [38].
In keeping with this manifestation of LF, serum AST activity
remained mostly within normal ranges in wild type C57BL/6
controls but was significantly elevated in the serum of HHD mice,
with a peak around day eight to twelve (Fig. 2A). To further
investigate how T cell responses restricted to H-2Kb/H-2Db and
to HLA-A2.1 influenced LASV control and disease, we crossed
HHD mice to C57BL/6 mice. C57BL/6 x HHD F1 mice express
H-2Kb, H-2Db and HLA-A2.1 molecules owing to hemizygosity at
all relevant genetic loci. C57BL/6 x HHD F1 mice controlled
LASV infection as efficiently as did C57BL/6 wild type mice, and
their AST levels remained within normal ranges (Fig. 2B, C). This
showed that H-2Kb/H-2Db-mediated virus control prevented
disease even in the presence of the HLA-A2.1 molecule. At first it
suggested also that persistent and high virus load was directly
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Figure 1. MHC-I but not MHC-II determines efficient LASV control. Mice of the indicated genotypes were infected with LASV. A, B: Blood
samples were collected over time to determine viremia. A: The 2.5 hrs, 2 day and 4 day time points (left part of panel A) were determined in one
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responsible for pathogenesis. Contrary to this notion, however, the
experiments in MHC-I-deficient mice had not resulted in obvious
disease despite persistent high-level viremia. This raised the
possibility that primary T cell responses may contribute to LF in
an immunopathological fashion, similar to the role of memory T
cell responses in DHF [10,11,39]. To address this possibility, we
infected HHD mice with LASV, and prior to infection depleted
either CD8+ T cells or CD4+ T cells or both using monoclonal
antibodies. MHC-I-/- mice are devoid of a CD8+ T cell
compartment and were also included in the experiment. Unlike
in untreated HHD mice and irrespective of comparably high levels
of viremia in all groups (Fig. 2E), serum AST levels of CD8/CD4-
double-depleted HHD mice remained in normal ranges (Fig. 2D).
Also, depletion of only CD4+ or CD8+ T cells or genetic deficiency
for MHC-I (affecting the CD8+ but not the CD4+ T cell
compartment) afforded at least partial protection. In agreement
with the results shown in Figs. 1B and 1C, these data suggested
that T cells of HHD mice were unable to significantly influence
viremia. Nevertheless CD8+ and CD4+ T cells played apparently
an essential role in the pathogenesis of LF in HHD mice.
Mopeia virus-induced T cell immunity protects HHD mice
against Lassa fever
To further characterize the role of T cells in the HHD mouse
model for LF, we analyzed whether such animals could be
immunized against LASV. For this, we used Mopeia virus (MV),
an apathogenic close relative of LASV. MV infection is known to
elicit heterologous immunity against LASV in monkeys (analogous
to vaccinia virus protecting against smallpox), and MV and
recombinants thereof have therefore been postulated as LASV
vaccines [40,41]. MV infection of HHD mice did not result in
detectable viremia (Fig. 3A) nor was AST elevation recorded at
any time point (Fig. 3B). This pattern of susceptibility of HHD
mice to LASV but not MV reflected the one reported in non-
human primates [40]. Next we tested whether MV immunization
could induce HLA-A2.1-restricted immunity against LF. A recent
study has characterized HLA-A2.1-restricted T cell epitopes in the
glycoprotein (GP) of LASV [42]. Here we found that MV infection
of HHD mice elicited high frequencies of CD8+ T cells specific for
the GP42-50 epitope of LASV and a somewhat weaker but clearly
detectable response against the GP60-68 epitope (Fig. 3C). CD8+
T cells specific for a third known epitope in LASV-GP (GP441-
449) were not induced to a detectable extent, owing to only partial
sequence homology of MV and LASV. When subsequently
challenged with LASV, MV immunization prevented viremia
and serum AST elevation in HHD mice (Fig. 3D, E), and by day
14 after challenge the spleen, liver, lung and kidney of MV-
immunized mice were free of detectable LASV (data not shown).
MV and LASV are serologically distinct i.e. neutralizing antibodies
elicited against one virus do not crossreact nor crossprotect against
the other [43]. This suggested that T cell immunity protected MV-
immunized HHD mice against subsequent LASV challenge
(Fig. 3D, E), albeit primary T cell responses facilitated apparently
the disease process in unvaccinated animals (Fig. 2D).
Histopathological alterations in diseased HHD mice are
reminiscent of human Lassa fever and depend on T cells
Next we set out to characterize tissue alterations in LASV-
infected HHD mice and to study their dependence on T cells. In
all LASV-infected HHD mice analyzed, the lung showed severe
pneumonitis with interlobular septal thickening and collapse of the
alveolar lumen (Fig. 4A, B). In addition, macroscopic analysis at
necropsy or in terminally diseased animals often revealed a
substantial pleural effusion (up to about 0.5 ml in each
hemithorax, not shown). Both observations matched those in
human LF [30,31]. In contrast to HHD mice, the lungs of
C57BL/6 sacrificed at the same time point were only mildly
affected or appeared normal (Fig. 4A, B). CD8/CD4-depletion
prevented these alterations in HHD mice, and also MHC-I-/- mice
exhibited considerably milder signs of peumonitis. Interestingly,
HHD lungs contained dense infiltrations of rounded Iba-I+
monocyte/macrophage lineage cells (Fig. 4C), a finding that was
less prominent or absent in C57BL/6 mice, T cell-depleted HHD
mice or MHC-I-/- mice. Accumulation of T cells was also noted in
HHD lungs (Fig. 4D) albeit to a lesser extent than for monocytes/
macrophages (compare Fig. 4C). Moreover, similar infiltrations
were also found in resistant C57BL/6 wild type mice and thus did
not correlate with disease.
In the liver, nodules of mononuclear cells were found around
the portal fields of all four groups of mice (Fig. 4E). Striking
differences were, however, noted in the distribution, shape and
orientation of hepatic monocyte/macrophage populations (includ-
ing Kupffer cells, Fig. 4F). Like in uninfected mice, hepatic
monocytes/macrophages of C57BL/6 and of T cell-depleted
HHD mice formed predominantly a flat layer along liver
sinusoids, oriented towards the central vein in a stellar pattern.
In contrast, the architecture of this cell layer was disrupted in
HHD mice (unless depleted of T cells) with the remaining cells
enlarged, rounded up, disorganized and often accumulated in
clusters, indicative of cellular activation and reminiscent of the
vigorous hepatic macrophage response reported from human LF
[29,30,31,32,33]. MHC-I-/- mice displayed an intermediate
picture with only moderate monocyte/macrophage activation.
Conversely, T cells were scattered at similarly moderate density
throughout the liver parenchyma and in periportal inflammatory
nodules of HHD and C57BL/6 mice (Fig. 4G and data not
shown). The number of hepatic T cells did therefore not correlate
with disease, similar to the findings in the lung.
Generalized immunosuppression is widely assumed to accentu-
ate viral hemorrhagic fever [6]. A recent monkey study has
tentatively attributed LASV immunosuppression to disorganiza-
tion of the microarchitecture in secondary lymphoid organs [44].
Here we found that LASV infection of HHD mice resulted in
disruption of the splenic white and red pulp compartments,
whereas the spleens of C57BL/6, CD8/CD4-depleted HHD mice
and MHC-I-/- mice were less affected (Fig. 4H). In correlation
with these alterations, the marginal zone macrophage layer was
lost in HHD mice but not in the other groups, and monocytes/
macrophages were homogenously distributed throughout the
splenic tissue of HHD mice (Fig. 4I). T cells were largely absent
in CD8/CD4-depleted mice, as expected, and were also somewhat
scarce in HHD mice (Fig. 4J), possibly indicating LASV-induced T
cell depletion as reported from non-human primates [44].
Monocytes/macrophages represent a major target of
LASV and produce IL-12p40 in a T cell-dependent fashion
The above morphological alterations had suggested T cell-
dependent monocyte/macrophage activation in LASV-infected
HHD mice. Classical activation of monocytes/macrophages e.g.
by the T cell cytokine interferon gamma and cell-to-cell contact
[45,46,47,48] triggers the secretion of NO and inflammatory
cytokines, and expression of the former is mediated by inducible
NO synthase (iNOS) [45,46,47,48,49]. iNOS expression can
therefore serve as a histological marker for inflammatory
differentiation of monocytes/macrophages [50]. On day 8 after
LASV infection we detected numerous iNOS-expressing mono-
cyte/macrophage clusters in the liver parenchyma of HHD mice
T Cell-Dependence of Lassa Fever Pathogenesis
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(Fig. 5A). Conversely, iNOS expression was not found in the liver
of C57BL/6 mice, CD8/CD4-depleted HHD mice or MHC-I-/-
mice infected with LASV. Furthermore, neither HHD nor
C57BL/6 mice displayed hepatic iNOS expression or morpho-
logical evidence of monocyte/macrophage activation when
assessed on day 2 and day 4 after infection (Fig. S1, analogous
data in lung and spleen not shown), i.e. prior to the onset of the
adaptive immune response.
Synthesis of the inflammatory cytokine subunit IL-12p40 is
restricted to macrophages, monocytes and dendritic cells, and its
production is greatly enhanced by T cell stimulation [48,51].
Within eight days after LASV infection, susceptible HHD mice
displayed vastly elevated serum IL12-p40 levels (Fig. 5B). Resistant
C57BL/6 mice showed comparably moderate IL-12p40 elevation.
In agreement with the above results on iNOS, IL-12p40 secretion
was strongly reduced by CD4/CD8-depletion in HHD mice, and
MHC-I-/- mice exhibited an intermediate IL-12p40 response.
Together, these findings suggested that T cells triggered an
inflammatory differentiation of monocytes/macrophages with
subsequent production of NO, IL-12p40 and likely other
inflammatory mediators (see Discussion section). This process
occurred, however, solely under conditions of unchecked LASV
replication i.e. in HHD mice but not in C57BL/6 mice where the
infection and thus the antigen were rapidly cleared.
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Figure 3. Mopeia virus (MV) infection is apathogenic in HHD mice but elicits LASV-specific HLA-A2.1-restricted CD8+ T cells and
protects against subsequent LASV challenge. A, B: HHD mice were infected with MV. Serum and blood samples were collected at the indicated
time points for measuring viremia (A) and AST (B), respectively. C: Epitope-specific CD8+ T cells in the spleen of MV-infected HHD mice were
measured on day 8 (naive controls did not display detectable responses, data not shown). The percent range of IFNc-producing CD8+ T cells is
indicated in the upper right quadrant. D, E: HHD mice, either naive or infected with MV two weeks previously, were challenged with LASV. Viremia (D)
and serum AST activity (E) were measured at the indicated time points. Symbols represent the mean 6SEM of four to five mice per group and time
point.
doi:10.1371/journal.ppat.1000836.g003
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Figure 4. T cell- and MHC-I-dependent alterations in the tissues of LASV-infected mice. HHD, C57BL/6, HHD mice depleted of CD8+ and
CD4+ T cells, and MHC-I-/- mice were infected with LASV. Eight days later, lung (A-D), liver (E-G) and spleen (H-J) tissue was processed for histological
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We had noted high virus loads in lung, liver and spleen of HHD
mice (Fig. 1C) where the above pathological changes were found.
The cellular distribution of LASV in vivo remains unknown, albeit
the virus has been shown to replicate productively in cultured
primate macrophages and dendritic cells [21,52,53]. To better
understand how viral replication might be associated with disease
we assessed virus distribution in tissues by immunohistochemistry
on day eight after infection (Fig. 5C). LASV nucleoprotein (NP)
was readily detected in a distinct population of cells in lung, liver
and spleen. Morphological criteria suggested that these cells were
predominantly monocytes/macrophages. We therefore performed
immunofluorescence double-stains for LASV nucleoprotein
(LASV-NP) and the monocyte/macrophage marker Iba-I
(Fig. 5D). By this method, 8266.8% of LASV-NP+ cells in liver,
6568.5% in the lung and 79611% in the spleen (mean6SD of six
mice) could be identified as monocytes/macrophages, suggesting
that they served as a major target of LASV.
Discussion
The data in mice presented here suggest a dual role for T cells
during LASV infection: T cells appear essential for rapid clearance
of the virus, but if failing to do so they may play a key role in the
ensuing disease process, too. Involvement of T cells in the
pathogenesis of viral hemorrhagic fever has precedence in Dengue
virus infection [10,11,39]. Unlike dengue hemorrhagic fever
(DHF), where ‘‘original antigenic sin’’ of memory T cells appears
to be involved, our findings suggest that T cell responses can have
disease-enhancing effects during primary LASV infection. Impor-
tantly, we do not exclude roles for memory T cells in addition, but
such aspects remain to be investigated (see below).
Our experiments modeled three prototypic scenarios of LASV-
host balance, as defined by the parameters ‘‘T cells’’ (relative
efficacy of antiviral T cell responses) and ‘‘Virus’’ (persistent virus
load), thus delineating the extremes of a spectrum and resulting in
the following outcomes:
I) T cells+ Virus2: Rapid and efficient virus control by T cells
prevents disease (naive C57BL/6 and vaccinated HHD mice).
II) ‘‘T cells+ Virus+’’: An antiviral T cell response of
intermediate efficiency fails at eliminating the virus, but
triggers severe disease (naive HHD mice).
III) ‘‘T cells2 Virus+’’: Complete absence of T cell defense
allows LASV persistence, and results in only mild or absent
disease (CD8/CD4-depleted HHD mice; partial protection
in MHC-I-/- mice).
Several mechanisms can be envisaged by which T cell responses
enhance LF [10,11,39] but additional studies will be needed to
address them directly. The histological picture in HHD mice
supports the current view [7] that direct T cell-mediated cytolysis
[54] unlikely is the main mechanism responsible for the tissue
damage in LF, such as hepatocyte death with subsequent AST
release. Based on the available evidence we postulate that during
persisting viremia, T cells continuously encounter LASV epitopes
on infected monocytes/macrophages in MHC-I and MHC-II
context (Fig. 5E). Additional interaction via co-stimulatory
molecules, or stimulation via T cell cytokines may trigger infected
monocytes/macrophages to differentiate and subsequently secrete
inflammatory mediators of their own [45,48,49,51]. Overstimula-
tion of macrophages can result in severe hepatic and pulmonary
damage besides mediating a shock syndrome [26,55,56], and such
overstimulation provides a plausible mechanism for indirect T cell
involvement in LF pathogenesis. LASV and related viruses are
known to replicate in cultured macrophages without causing
cellular activation or production of inflammatory cytokines
[21,52,53]. Hence, classical T cell-driven monocyte/macrophage
activation by IFNc and direct cell-to-cell contact [45,46,47,48]
may augment inflammatory differentiation and cytokine release
from LASV-infected monocytes/macrophages in vivo [19,21,22],
similar to the ability of LPS to induce the activation of LASV-
infected macrophages in culture [21,52,53]. T cell stimulation may
thus facilitate a systemic inflammatory condition [57] as a
potential pathogenetic correlate of the diverse and non-specific
clinical manifestations of LF.
This view of the role of T cells in LF correlates well with our
observations in scenario I, where one would predict that efficient
virus elimination by C57BL/6 and immune HHD mice results in
only short and transient antigen presentation on a limited number
of infected monocytes/macrophages, and therewith lack of
disease, as was indeed found. Similarly, the concept explains our
findings in scenario III, where the absence of T cells to properly
activate infected monocytes/macrophages in CD8/CD4-depleted
HHD mice results in mild or absent disease.
In addition, at least two – seemingly paradoxical – observations in
LASV-infected non-human primates would support our mechanistic
postulate. The first observation is that high doses of LASV tend to
be less lethal than low ones [28]. This phenomenon may be
explained through the mechanisms of T cell ‘‘exhaustion’’ or
‘‘deletion’’ under high virus loads [58]. As such, a high initial virus
inoculum may weaken the T cell response, thus attenuating disease
through shifting conditions from scenario II towards scenario III.
The second paradoxical observation stems from a vaccination
study, in which a recombinant vaccinia virus expressing the NP
protein of LASV was used in monkeys. The vaccine turned out to
protect only a minority of the animals and, intriguingly, those
LASV-challenged monkeys not protected by the vaccine displayed
a more acute form of disease than control monkeys that had not
been vaccinated at all [34]. A likely explanation may be that,
although the vaccination may not have protected all animals, the
still accelerated (memory) T cell response of non-protected animals
also accelerated their disease process. Support for such a scenario
comes from infection of mice with another arenavirus, lympho-
cytic choriomeningitis virus (LCMV). LCMV-induced immuno-
pathological disease of the central nervous system is T cell-
dependent and, similar to the observation with LASV in monkeys,
can be enhanced by prior vaccination with recombinant vaccinia
viruses expressing LCMV antigens [59].
Last but not least, our study introduces a mouse model for LF,
the lack of which has long hampered progress in this field of
research. Only the general versatility of the mouse as a research
model, including the availability of gene-targeted strains, makes
mechanistic studies as presented here possible. Despite certain
shortcomings as listed below, we think that the humanized mouse
model could prove useful in further studies on LF pathogenesis,
analysis. H/E (A, B, E, H) or immunohistochemical staining of monocytes/macrophages (Iba-1; C, F, I) and T cells (CD3; D, G, J) are shown. Note the
collapsed alveolar space, rounded and irregularly distributed monocytes/macrophages in liver and disruption of the splenic microarchitecture in
LASV-infected HHD mice. These changes are less severe or largely restored in C57/BL/6 and CD8/CD4-depleted HHD mice, respectively, whereas
MHC-I-/- mice display an intermediate picture. Magnification bars indicate 1000 mm (A), 100 mm (B), 50 mm (C, D, F), 30 mm E,G) and 200 mm (H-J),
respectively.
doi:10.1371/journal.ppat.1000836.g004
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especially as the model lends itself well to the assessment of CD8+
T cell-based vaccines (compare Fig. 3). Although the ,20%
lethality we found in HHD mice using the Ba366 strain of LASV
may contrast with the uniform lethality observed in LASV strain
Josiah-infected strain 13 guinea pigs or monkeys [28], our lethality
rates match those reported for Josiah-infected outbred Hartley
guinea pigs [60], as well as inbred strain 13 and strain 2 guinea
pigs inoculated with other LASV isolates [61]. Nevertheless, we
cannot exclude the possibility that the HHD model fails to recreate
certain aspects of human LF.
For the mechanistic analyses presented here, we used relatively
high intravenous LASV doses of 106 PFU. The need for such doses
to cause severe disease likely reflects the imperfect adaptation of
LASV to mice (compare also the Methods section). However,
preliminary experiments indicate that viremia and AST elevation
can already be observed at lower doses, albeit with higher
variability, and that LASV can replicate in HHD mice after
subcutaneous administration (data not shown). We would
therefore argue that viremia and AST elevation in HHD mice
may represent useful surrogates [38] to assess vaccine efficacy
prior to an eventual confirmation in non-human primates.
T cell densities in the spleen of LASV-infected HHD and
C57BL/6 mice were comparable (day 8: 33396925 CD3+ cells/
mm2 in HHD mice, 382662057 CD3+ cells/mm2 in C57BL/6
mice; mean6SD, n= 6; p = 0.61), arguing against preferential T
cell depletion [44] as a potential reason for defective virus control
in HHD mice. To characterize disease enhancing (HHD) vs.
protective (C57BL/6) primary T cell responses against LASV,
future studies will need to compare the magnitude, kinetics and
effector-/cytokine-profile [62] of LASV epitope-specific CD4+ and
CD8+ T cell responses. Similarly, serum IL-12p40 and iNOS
expression have served as surrogates of the inflammatory
monocyte/macrophage response in this study, but future work
will have to determine its breadth in terms of cytokines,
chemokines and inflammatory mediators such as NO, leukotrienes
and prostaglandins, their production in tissues and systemic
dissemination in blood. The experimental depletion and/or
inhibition of monocyte/macrophage populations and of inflam-
matory mediators may provide additional insights into the cellular
and molecular players in LF, indicating to which extent the
‘‘cytokine storm’’ hypothesis [57] can explain LF pathogenesis.
With the availability of a mouse model for LASV such studies
become possible, although the necessity for BSL-4 laboratory
containment can represent a major practical hurdle.
Taken together, our results in mice suggest a two faced role of T
cells in LASV infection, both in virus control and also in
enhancing LF pathogenesis. This extends our understanding of
LASV-host interactions and raises the possibility that heterogene-
ity in MHC-I and in overall T cell immunocompetence represents
one explanation for the wide spectrum of clinical outcomes in a
human population exposed to LASV [2]. Perhaps even more
important, we think that beside beneficial also detrimental aspects
of T cell-responses and -immunity [34,59] should be given
thorough consideration in future strategies for LF vaccine design.
Materials and Methods
Mice and animal experiments
C57BL/6, b2-microglobulin-deficient mice (MHC-I-/-) [63],
MHC-II-/- [64] and HHD [37] mice were bred at the Institute for
Laboratory Animal Sciences, University of Zurich, Switzerland.
Experiments with Lassa virus were performed in the BSL-4 unit of
the Bernhard Nocht Institute, Hamburg, Germany. Experiments
with Mopeia virus were performed at the University of Geneva
and at the University Hospital of Zurich, Switzerland. Permission
for animal experiments was obtained from the authorities of the
Freie und Hansestadt Hamburg, and from the Cantonal
authorities of Geneva and Zurich, Switzerland, respectively. All
experiments were performed in accordance with the Swiss and
German law for animal protection, respectively.
Viruses, virus titration, infection and T cell depletion of
mice
This model is based on the Ba366 [65] strain of LASV. Pilot
experiments with a range of isolates representing the different
endemic areas (Josiah, Sierra Leone; Lib90, Liberia; Ba366,
Guinea; AV, Ivory coast/Burkina Faso; CSF, Nigeria) had
indicated that Ba366 was the virus that most efficiently replicated
in HHD mice. LASV and Mopeia virus (AN21366), were grown on
BHK21 and Vero cells, respectively, and were administered to mice
at a dose of 106 PFU i.v. unless stated differently. Virus stocks and
viral infectivity in blood samples were determined in immunofocus
assays as described [66]. CD8+ and/or CD4+ T cell populations
were depleted by i.p. administration of monoclonal antibodies
YTS169 (anti-CD8) and YTS191 (anti-CD4) on day -3 and day -1
of LASV infection as previously described [67]. The efficiency of
depletion was verified by flow cytometry and was .99%.
Blood biochemistry and histology
Serum AST and ALT activities were determined by using
commercially available colorimetric assay kits (Reflotron, Roche
Diagnostics, Germany). Mouse tissues were fixed in 4% formalin
and were embedded in paraffin. Sections were stained with
hematoxilin/eosin (H/E) or processed for immunohistochemistry
as follows: Upon inactivation of endogenous peroxidases (PBS/3%
hydrogen peroxide) and blocking (PBS/10% FCS) sections were
incubated with the primary antibodies rat anti-human CD3
(crossreactive with murine CD3 on mouse T cells; Serotec), rabbit
anti-Iba-1 (monocytes/macrophages, Wako Pure Chemical Indus-
tries) or rat anti-Lassa nucleoprotein (see below). Bound primary
antibodies were detected with biotinylated rat-specific (DakoCyto-
mation) or rabbit-specific (Amersham) secondary antibody, followed
by incubation with extraavidin peroxidase (Sigma Aldrich), and
bound peroxidase was visualized by 3,39-diaminobenzidine as
chromogen (Sigma Aldrich). Haemalaun was used for counterstain-
ing of nuclei. For fluorescence double labeling, primary antibodies
were visualized using species specific Cy3- or Cy2-conjugated
secondary antibodies (all from Jackson ImmunoResearch Labora-
tories Inc.) with DAPI (Sigma-Aldrich) nuclear staining. To
determine the percentage of monocytes/macrophages (Iba-1-
positive cells) amongst LASV-infected cells, a total of 41 (liver)
and 27 (lung) randomly captured 40x visual fields were analyzed.
Automated assessment of CD3+ T cell densities in spleen
sections
Histological spleen sections stained with anti-CD3 antibody (T
cells) and counterstained with Haemalaun (nuclei, see above) were
scanned using the Dotslide System (Olympus GmBH) at a 200-fold
magnification. For analysis, the images were automatically processed
Immunohistochemical staining of LASV-NP in lung, liver and spleen of HHD mice on day 8 after infection. D: Illustrative examples for cellular
colocalization of the monocyte/macrophage marker Iba-1 (red) and LASV-NP (green) in the liver. Magnification bars indicate 50 mm (A, C) and 10 mm
(D), respectively. E: Schematic describing the postulated mechanism how T cells may enhance LF pathogenesis.
doi:10.1371/journal.ppat.1000836.g005
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in a custom-programmed script of Cognition Network Language
based on the Definiens Cognition Network Technology platform
(Definiens Developer XD software). The Cognition Network
Language is an object-based procedural computer language,
designed for automated analysis of complex, context-dependent
image analysis. In brief, the programmed script first discriminates
spleen tissue and tissue-free surroundings by spectral difference
detection. The surface of the resulting region of interest (spleen
tissue, ROI) is calculated. Subsequently ‘‘CD3 positive cells’’ within
the ROI are detected based on brown anti-CD3 staining and are
counted, to calculate the number of CD3+ cells per mm2 of tissue.
ELISA
Serum IL-12p40 was determined using a sandwich ELISA kit
(eBioscience) according to the manufacturer’s instructions.
Generation of anti-LASV-NP serum
Recombinant NP of LASV strain BA366 was expressed in E.
coli using the pET28 expression vector system (Novagen).
Supernatants of pET28 constructs were purified using the Talon
Metal Affinity Resin (Clontech) in a batch procedure. Urea (8 M)
lysates were brought to nondenaturing conditions by increasingly
substituting the buffer for sonication buffer during the resin-batch
procedure. Proteins were eluted with 250 mM imidazole in
sonication buffer on a gravity column (Bio-Rad). Rat antisera
were raised against purified recombinant NP by s.c. immunization
with recombinant NP emulsified in complete Freund’s adjuvant
containing 1 mg of Mycobacterium tuberculosis (H37RA; Difco
Laboratories, Detroit, MI). Four weeks after the first immuniza-
tion, animals were boosted with recombinant NP emulsified in
incomplete Freund’s adjuvant (Difco). Terminal bleedings were
performed 4 weeks after the boost. The specificity of the anti-
LASV-NP antiserum was verified by immunofluorescence tests on
LASV-infected cells as well as on LASV-infected or non-infected
tissues. Pre-immune serum from the rats used for immunization
was included as a control in both settings.
Intracellular cytokine assay
Epitope-specific CD8+ T cells were enumerated by an
intracellular cytokine assay for IFNc as previously described
[68]. In brief, 106 splenocytes were incubated in 200 ml of IMDM
supplemented with 10% FCS and penicillin/streptomycin for 5 h
at 37uC at a 1026 M concentration of the LASV-GP-derived
peptide epitope GP42-50 (GLVGLVTFL), GP60-68 (SLYKG-
VYEL), GP441-449 (YLISIFLHL) or with medium alone as a
negative control. To enhance intracellular accumulation of IFN-c,
brefeldin A was added at a final concentration of 5 mg/ml for the
last 3.5 hours of culture. Subsequently, the cells were washed with
FACS buffer (PBS supplemented with 2% FCS, 0.01% NaN3 and
20 mM EDTA) and surface staining was performed with anti-
CD8b-PE and anti-B220-PerCP antibody conjugates (both from
BD Biosciences) for 30 min at 4uC. After washing twice with
FACS buffer, the cells were fixed with 100 ml of 4% paraformal-
dehyde in PBS for 5 min at 4uC. Two milliliters of permeabiliza-
tion buffer (FACS buffer supplemented with 0.1% w/v saponin,
Sigma) were added and the cells were incubated for 10 min at
4uC. Subsequently, they were spun down and stained intracellu-
larly with anti-mouse-IFNc-APC (BD Biosciences) in permeabili-
sation buffer for 60 min at 4uC. After two washes with
permeabilization buffer, the cells were resuspended in FACS
buffer and were analyzed on a FacsCalibur (Becton Dickinson).
FACS plots were gated on B2202 lymphocytes.
Statistical analysis
Between group differences were analyzed by 1-way ANOVA
and 2-way ANOVA for individual or multiple values of different
groups, respectively, followed by LSD post tests. SPSS vs. 13 was
used for analysis. P values ,0.05 were considered statistically
significant (indicated as * in figures). P,0.01 was considered
highly significant (indicated as ** in figures). P.0.05 was
considered as not significantly different (‘‘n.s.’’).
Supporting Information
Figure S1 Absence of detectable macrophage activation in the
early phase of LASV infection. HHD and C57BL/6 mice were
infected with LASV. Two, four and eight days later, liver tissue
was processed for histological analysis. Tissues of uninfected mice
served as reference. H/E staining and immunohistochemical
detection of monocytes/macrophages (Iba-1) and iNOS are
shown. Arrowheads point out clusters of iNOS-positive mono-
cytes/macrophages, which are found in day 8 LASV-infected
HHD mice only. Magnification bars indicate 50 mm (H/E) and
100 mm (monocytes/macrophages and iNOS), respectively. Rep-
resentative images from three mice per group and time point are
shown.
Found at: doi:10.1371/journal.ppat.1000836.s001 (11.44 MB
TIF)
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